Seegene will distribute and recommend Microbix’s QAPs for monitoring the workflow accuracy of Seegene Novaplex and Allplex assays used across the US. Credit: Tatiana from Pixabay.

Molecular assay provider Seegene USA has collaborated with Microbix Biosystems for the latter’s QAPS.

Under the deal, Seegene will supply and recommend the QAPs for monitoring the workflow accuracy of Seegene Novaplex and Allplex assays used across the US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Microbix QAPs are ready for use in polymerase chain reaction (PCR) based (molecular) assays designed for Copan FLOQSwabs in both room-temperature stable formats and liquid vials that remain stable at refrigerator temperatures.

Microbix PROCEEDx QAPs are designated as research use only (RUO) samples, whereas its REDx QAPs are classified as in-vitro diagnostic (IVD) controls.

Microbix business development SVP Phillip Caselli said: “Our longstanding relationship with Seegene Canada laid a strong foundation for this Microbix – Seegene USA relationship.

“Our collaboration naturally aligns the two companies to help assure optimal results for laboratories performing high-multiplex PCR testing using Seegene Assays.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

With this agreement, Seegene USA will now provide Microbix’s QAPs in addition to its existing range of high multiplex PCR assays.

These assays detect infectious disease pathogens and fall under Seegene’s Allplex and Novaplex brands.

Utilising Seegene’s technology, the assays have a distinctive capability to yield comprehensive results using just one channel in a PCR reaction.

Seegene USA marketing SVP Craig Howell said: “In this partnership, we are again increasing our IVD presence for the US and further supporting our lab customers in their mission to better provide quality results for their patients and institutions.

“As well, we believe our ongoing IVD assay development requires custom control and validation panel expertise that is met by Microbix’s competencies.”

In September 2023, Seegene and Springer Nature announced the ‘Open Innovation Program powered by Seegene’ (Open Innovation Program) for the development of syndromic quantitative PCR (qPCR) assays.

Available across the globe, the programme will allow scientists, clinicians and experts to develop the assays across all fields.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact